| |  Online-Ressource |
|---|
| Verfasst von: | Friedrich, Kilian [VerfasserIn]  |
|---|
| | Wannhoff, Andreas [VerfasserIn] |
|---|
| | Rupp, Christian [VerfasserIn] |
|---|
| | Mehrabi, Arianeb [VerfasserIn] |
|---|
| | Weiss, Karl Heinz [VerfasserIn] |
|---|
| | Gotthardt, Daniel [VerfasserIn] |
|---|
| Titel: | Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis |
|---|
| Verf.angabe: | Kilian Friedrich, Carina Baumann, Andreas Wannhoff, Christian Rupp, Arianeb Mehrabi, Karl Heinz Weiss, Daniel N. Gotthardt |
|---|
| Jahr: | 2018 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Gesehen am 10.12.2019 |
|---|
| Titel Quelle: | Enthalten in: Journal of gastrointestinal and liver diseases |
|---|
| Ort Quelle: | Cluj-Napoca : Soc., 2006 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | 27(2018), 2, Seite 145-150 |
|---|
| ISSN Quelle: | 1842-1121 |
|---|
| Abstract: | BACKGROUND AND AIMS: The disease course of primary sclerosing cholangitis (PSC) is variable and difficult to predict. MicroRNA-122 (miR-122) is associated with various liver diseases. We investigated the value of miR-122 as a biomarker for the disease course of PSC. - METHODS: We determined serum miR-122 levels in a long-term, prospective cohort of 114 PSC patients and a second validation cohort. - RESULTS: Based on miR-122 levels, PSC patients were assigned to low or high level miR-122 groups. Kaplan-Meier analysis showed significantly impaired actuarial transplant-free survival for PSC patients in the low miR-122 group (mean: 46.1 +/- 4.1 months; 95% confidence intervals [CI]: 38.1-54.2) compared to the high miR-122 group (mean: 95.2 +/- 7.9 months; 95% CI: 79.5-110.8; p = 0.034). Using a multivariate Cox's proportional hazards model approach, Mayo-Risk score (odds ratio [OR]: 1.47; 95% CI: 1.13‒1.92; p = 0.004), the presence of dominant strictures (OR: 2.62; 95% CI: 1.00‒5.55; p = 0.004), and serum miR-122 levels (OR: 1.19; 95% CI: 1.00‒1.43; p = 0.045) were independent risk factors associated with reduced actuarial transplant-free survival. We were able to confirm this finding in a second, independent cohort of PSC patients (low miR-122 group: mean survival: 13.1 +/- 5.2 months; 95% CI: 2.8-23.4; high miR-122 group: mean: 28.62 +/- 4.2 months; 95% CI: 20.3-37.0; p = 0.018). - CONCLUSIONS: We identified miR-122 as a novel, independent prognostic biomarker associated with improved survival in PSC patients. It is unknown whether exogenous miR-122 might influence the disease course of PSC patients. . |
|---|
| DOI: | doi:10.15403/jgld.2014.1121.272.cho |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: http://dx.doi.org/10.15403/jgld.2014.1121.272.cho |
|---|
| | DOI: https://doi.org/10.15403/jgld.2014.1121.272.cho |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Adolescent |
|---|
| | Adult |
|---|
| | Biomarkers |
|---|
| | Cholangitis, Sclerosing |
|---|
| | Female |
|---|
| | Follow-Up Studies |
|---|
| | Humans |
|---|
| | Kaplan-Meier Estimate |
|---|
| | Liver Transplantation |
|---|
| | Male |
|---|
| | MicroRNAs |
|---|
| | Middle Aged |
|---|
| | Prognosis |
|---|
| | Prospective Studies |
|---|
| | Risk Factors |
|---|
| | Severity of Illness Index |
|---|
| | Young Adult |
|---|
| K10plus-PPN: | 1684898501 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis / Friedrich, Kilian [VerfasserIn]; 2018 (Online-Ressource)
